Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zushima, also known as Cortex Daphnes, is a traditional Chinese medicine derived from the processed stem and root barks of plants in the genus *Daphne*, primarily *Daphne giraldii*, *Daphne tangutica*, and *Daphne retusa*. It is utilized in various topical formulations, such as patches and sprays, for its analgesic and anti-inflammatory properties. The drug is primarily indicated for the symptomatic treatment of knee osteoarthritis (OA), joint pain, rheumatoid arthritis, and soft tissue injuries. Its therapeutic effect is attributed to active phytochemicals like daphnetin, which inhibit the production of prostaglandin E2 by suppressing cyclooxygenase-2 (COX-2) expression. Clinical evidence, including multicenter non-inferiority trials, suggests that Zushima patches provide pain relief and functional improvement comparable to topical nonsteroidal anti-inflammatory drugs (NSAIDs) like indomethacin, though they are associated with a higher incidence of mild-to-moderate skin irritation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zushima.